119 related articles for article (PubMed ID: 38130162)
21. Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis.
Hwang IG; Song HS; Lee MA; Nam EM; Lim J; Lee KH; Lee KT; Zang DY; Jang JS
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1291-6. PubMed ID: 25326056
[TBL] [Abstract][Full Text] [Related]
22. Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.
Fornaro L; Vivaldi C; Cereda S; Leone F; Aprile G; Lonardi S; Silvestris N; Santini D; Milella M; Caparello C; Musettini G; Pasquini G; Falcone A; Brandi G; Sperduti I; Vasile E;
J Exp Clin Cancer Res; 2015 Dec; 34():156. PubMed ID: 26693938
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
Woo SM; Lee WJ; Kim JH; Kim DH; Han SS; Park SJ; Kim TH; Lee JH; Koh YH; Hong EK
Chemotherapy; 2013; 59(3):232-8. PubMed ID: 24356333
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study.
Bi P; Wang X; Liu R; Li X; Wei S; Zhao J; Tan X; Zhang F; Mao Q; Zhang Y; Tang B; Xun X; Guo R; Zheng K; Zhou S; Tang S
Surg Open Sci; 2023 Dec; 16():171-183. PubMed ID: 38026829
[TBL] [Abstract][Full Text] [Related]
25. Histologic subtype-based evaluation of recurrence and survival outcomes in patients with adenocarcinoma of the ampulla of Vater.
Park SJ; Shin K; Hong TH; Lee SH; Kim IH; Kim Y; Lee M
Sci Rep; 2023 Oct; 13(1):16547. PubMed ID: 37783755
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
André T; Tournigand C; Rosmorduc O; Provent S; Maindrault-Goebel F; Avenin D; Selle F; Paye F; Hannoun L; Houry S; Gayet B; Lotz JP; de Gramont A; Louvet C;
Ann Oncol; 2004 Sep; 15(9):1339-43. PubMed ID: 15319238
[TBL] [Abstract][Full Text] [Related]
28. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer.
Park K; Kim KP; Park S; Chang HM
Asia Pac J Clin Oncol; 2017 Feb; 13(1):13-20. PubMed ID: 27770489
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
[TBL] [Abstract][Full Text] [Related]
30. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
31. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy.
Uson Junior PLS; Majeed U; Yin J; Botrus G; Sonbol MB; Ahn DH; Starr JS; Jones JC; Babiker H; Inabinett SR; Wylie N; Boyle AWR; Bekaii-Saab TS; Gores GJ; Smoot R; Barrett M; Nagalo B; Meurice N; Elliott N; Petit J; Zhou Y; Arora M; Dumbauld C; Barro O; Baker A; Bogenberger J; Buetow K; Mansfield A; Mody K; Borad MJ
JCO Precis Oncol; 2022 Jun; 6(1):e2100274. PubMed ID: 35666960
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China.
Zhang L; Wang LY; Deng YM; Wang FH; Feng F; Chen YC; An X; Chen C; Xu RH; Li YH
J BUON; 2011; 16(4):689-96. PubMed ID: 22331723
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy and radiotherapy for advanced pancreatic cancer.
Chin V; Nagrial A; Sjoquist K; O'Connor CA; Chantrill L; Biankin AV; Scholten RJ; Yip D
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011044. PubMed ID: 29557103
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
[TBL] [Abstract][Full Text] [Related]
35. Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Hitchen N; Waldron NR; Deva S; Findlay M; Lawrence B
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e231-e238. PubMed ID: 36114593
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers.
Jensen LH; Andersen RF; Byriel L; Fernebro E; Jakobsen A; Lindebjerg J; Nottelmann L; Ploen J; Hansen TF
Acta Oncol; 2020 Mar; 59(3):298-301. PubMed ID: 31838939
[No Abstract] [Full Text] [Related]
37. First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
Lin Z; Fu S; Zhou Y; Zhang X; Chen C; He LN; Li H; Wang Y; Chen T; Zhang L; Hong S
Lung Cancer; 2019 Nov; 137():100-107. PubMed ID: 31568886
[TBL] [Abstract][Full Text] [Related]
38. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
[TBL] [Abstract][Full Text] [Related]
39. Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial).
Kosugi C; Koda K; Denda T; Ishibashi K; Ishida H; Seike K; Sakata H; Yanagisawa S; Miyazaki A; Takayama W; Koike N; Shimizu H; Matsubara H
Int J Colorectal Dis; 2021 Dec; 36(12):2637-2647. PubMed ID: 34368890
[TBL] [Abstract][Full Text] [Related]
40. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.
Demols A; Borbath I; Van den Eynde M; Houbiers G; Peeters M; Marechal R; Delaunoit T; Goemine JC; Laurent S; Holbrechts S; Paesmans M; Van Laethem JL
Ann Oncol; 2020 Sep; 31(9):1169-1177. PubMed ID: 32464280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]